Bio-Rad Laboratories Inc - Asset Resilience Ratio
Bio-Rad Laboratories Inc (BIO-B) has an Asset Resilience Ratio of 9.83% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Bio-Rad Laboratories Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2003–2024)
This chart shows how Bio-Rad Laboratories Inc's Asset Resilience Ratio has changed over time. See BIO-B net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Bio-Rad Laboratories Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see BIO-B company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.00 Billion | 9.83% |
| Total Liquid Assets | $1.00 Billion | 9.83% |
Asset Resilience Insights
- Limited Liquidity: Bio-Rad Laboratories Inc maintains only 9.83% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bio-Rad Laboratories Inc Industry Peers by Asset Resilience Ratio
Compare Bio-Rad Laboratories Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for Bio-Rad Laboratories Inc (2003–2024)
The table below shows the annual Asset Resilience Ratio data for Bio-Rad Laboratories Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 12.56% | $1.18 Billion | $9.36 Billion | +2.78pp |
| 2023-12-31 | 9.78% | $1.20 Billion | $12.30 Billion | -0.26pp |
| 2022-12-31 | 10.05% | $1.36 Billion | $13.50 Billion | +7.80pp |
| 2021-12-31 | 2.24% | $399.13 Million | $17.80 Billion | -0.29pp |
| 2020-12-31 | 2.54% | $328.91 Million | $12.97 Billion | -3.13pp |
| 2019-12-31 | 5.67% | $453.97 Million | $8.01 Billion | -1.70pp |
| 2018-12-31 | 7.37% | $413.27 Million | $5.61 Billion | -1.32pp |
| 2017-12-31 | 8.69% | $371.15 Million | $4.27 Billion | -1.27pp |
| 2016-12-31 | 9.95% | $383.18 Million | $3.85 Billion | +1.09pp |
| 2015-12-31 | 8.86% | $328.72 Million | $3.71 Billion | +0.35pp |
| 2014-12-31 | 8.51% | $284.38 Million | $3.34 Billion | +0.33pp |
| 2013-12-31 | 8.18% | $277.37 Million | $3.39 Billion | -5.11pp |
| 2012-12-31 | 13.29% | $457.69 Million | $3.44 Billion | +5.58pp |
| 2011-12-31 | 7.71% | $238.88 Million | $3.10 Billion | +3.84pp |
| 2010-12-31 | 3.87% | $118.64 Million | $3.06 Billion | +0.13pp |
| 2009-12-31 | 3.74% | $94.88 Million | $2.54 Billion | +1.83pp |
| 2008-12-31 | 1.91% | $38.95 Million | $2.04 Billion | -1.23pp |
| 2007-12-31 | 3.14% | $61.98 Million | $1.97 Billion | -13.43pp |
| 2006-12-31 | 16.57% | $264.47 Million | $1.60 Billion | +8.41pp |
| 2005-12-31 | 8.16% | $116.34 Million | $1.43 Billion | -3.94pp |
| 2004-12-31 | 12.10% | $165.90 Million | $1.37 Billion | +3.71pp |
| 2003-12-31 | 8.39% | $83.25 Million | $992.60 Million | -- |
About Bio-Rad Laboratories Inc
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biolog… Read more